Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof. Formula (I).

The invention provides Saxagliptin Schiff bases, polymorphs of Saxagliptin and ( 1 S,3S,5S)-2-[(2S)-2-propan-2-y lideneamino-2-(3-hydroxy- 1 -adamanty l)acetyl]- 2-azabicyclo[3.1.0]hexane-3-carbonitrile, processes for preparing Saxagliptin hydrates, and pharmaceutical compositions thereof.

Crystalline forms of Sitagliptin salts, processes for preparing crystalline forms of Sitagliptin salts, and pharmaceutical compositions of Sitagliptin salts are provided.

The disclosure relates to a pharmaceutical composition comprising a granulate of a mixture of: a) rosiglitazone maleate;b) at least one pharmaceutically acceptable carrier;and c) less than 0.1% of the compound of the formula (I): based on the combined weight of the compound of the formula (I) and rosiglitazone maleate.

The present invention relates to a novel salt of perindopril, namely the paratoluene sulfonic acid salt. The present invention also relates to an amorphous form of the perindopril paratoluene sulfonic acid salt. The invention further relates to processes for the preparation of the novel salt and the amorphous form thereof. The invention also relates to pharmaceutical compositions comprising the perindopril tosylate for the treatment of hypertension and heart failure.